B Braun Company Profile

What is the competitive landscape for B BRAUN

B BRAUN has one hundred and twenty-two approved drugs.

There are three US patents protecting B BRAUN drugs.

There are fifty patent family members on B BRAUN drugs in twenty-nine countries and two hundred and fifty-eight supplementary protection certificates in seventeen countries.

Summary for B Braun

International Patents:	50
US Patents:	3
Tradenames:	230
Ingredients:	68
NDAs:	122

Drugs and US Patents for B Braun

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
B Braun	THEOPHYLLINE 0.08% AND DEXTROSE 5% IN PLASTIC CONTAINER	theophylline	INJECTABLE;INJECTION	019083-002	Nov 7, 1984		DISCN	No	No
B Braun	HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	heparin sodium	INJECTABLE;INJECTION	019802-003	Jul 20, 1992		DISCN	No	No
B Braun	HYPROTIGEN 5%	protein hydrolysate	INJECTABLE;INJECTION	006170-003	Jan 10, 1984		DISCN	No	No
B Braun Medical	LEVETIRACETAM IN SODIUM CHLORIDE	levetiracetam	INJECTABLE;INTRAVENOUS	209705-003	Feb 27, 2024	AP	RX	No	No
B Braun	THEOPHYLLINE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER	theophylline	INJECTABLE;INJECTION	019212-002	Nov 7, 1984		DISCN	No	No
B Braun	THEOPHYLLINE 0.16% AND DEXTROSE 5% IN PLASTIC CONTAINER	theophylline	INJECTABLE;INJECTION	019826-003	Aug 14, 1992		DISCN	Yes	No
B Braun	HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	heparin sodium	INJECTABLE;INJECTION	019135-001	Mar 29, 1985		DISCN	No	No

Expired US Patents for B Braun

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
B Braun	HEPATAMINE 8%	amino acids	INJECTABLE;INJECTION	018676-001	Aug 3, 1982	3,950,529
B Braun	UCEPHAN	sodium benzoate; sodium phenylacetate	SOLUTION;ORAL	019530-001	Dec 23, 1987	4,284,647

International Patents for B Braun Drugs

Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	2014091420
Serbia	56060
South Korea	20150085131
Japan	2009507807
Canada	2878714
South Africa	201504618
Serbia	53077

Supplementary Protection Certificates for B Braun Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2932970	201840031	Slovenia		PRODUCT NAME: COMBINATION OF DOLUTEGRAVIR OR ITS PHARMACEUTICALLY ACCEPTABLE SALT, FOR EXAMPLE SODIUM SALT, AND RILPIVIRINE OR ITS PHARMACEUTICALLY ACCEPTABLE SALT, FOR EXAMPLE RILPIVIRINE HYDROCHLORIDE; NATIONAL AUTHORISATION NUMBER: EU/1/18/1282/001-002; DATE OF NATIONAL AUTHORISATION: 20180516; AUTHORITY FOR NATIONAL AUTHORISATION: EU
0957929	SPC/GB06/021	United Kingdom		PRODUCT NAME: PEGAPTANIB, PREFERABLY IN THE FORM OF ITS SODIUM SALT; REGISTERED: UK EU/1/05/325/001 20060201
2404919	PA2016015,C2404919	Lithuania		PRODUCT NAME: 3-(6-((1-(2,2-DIFLUOR-1,3-BENZODIOKSOL-5-IL)CIKLOPROPANKARBONIL)AMINO)-3-METILPIRIDIN-2-IL)BENZOINE RUGSTIS ARBA JOS FARMACINIU POZIURIU PRIIMTINA DRUSKA ARBA ESTERIS; REGISTRATION NO/DATE: EU/1/15/1059 20151119
1259550	122008000068	Germany		PRODUCT NAME: SUGAMMADEX ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/08/466/001-002 20080725
1499331	13C0055	France		PRODUCT NAME: SULFATE DE SODIUM ANHYDRE, SULFATE DE MAGNESIUM HEPTAHYDRATE, SULFATE DE POTASSIUM; NAT. REGISTRATION NO/DATE: NL41696 20130426; FIRST REGISTRATION: BE - 434323 20130220
2340828	LUC00195	Luxembourg		PRODUCT NAME: SACUBITRIL ET VALSARTAN, SOUS FORME DE COMPLEXE DE SEL DE SODIUM SACUBITRIL VALSARTAN, C'EST-A-DIRE (((S)-N-VALERYL-N-((2'-(1H-TETRAZOLE-5-YL)-BIPHENYL-4-YL)-METHYL)-VALINE) ((2R,4S)-5-BIPHENYL-4-YL-4-(3-CARBOXY-PROPIONYLAMINO)-2-METHYL-ESTER ETHYLIQUE D'ACIDE PENTANOIQUE))NA3 X H2O, DANS LEQUEL X EST 0 A 3; AUTHORISATION NUMBER AND DATE: EU/1/15/1058 20151123
2377536	25/2013	Austria		PRODUCT NAME: 4-AMINOPYRIDIN ODER DESSEN SALZE; REGISTRATION NO/DATE: EU/1/11/699/001-002 20110720

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• B Braun
• B Braun Medical

Pharmaceutical Competitive Landscape Analysis: B. Braun – Market Position, Strengths & Strategic Insights

Last updated: February 20, 2026

What is B. Braun's Position in the Pharmaceutical Industry?

B. Braun operates primarily in healthcare products and services, with a focus on infusion therapies, critical care, and surgical instruments. It maintains a strong presence in hospital settings across North America, Europe, and Asia. Although not a conventional pharmaceutical company, it develops and supplies active pharmaceutical ingredients (APIs), particularly in anesthesia, pain management, and specialty therapies.

Market Share and Revenue (2022):

• Total revenue: €8.1 billion
• Pharmaceuticals segment accounts for approximately 12% (€972 million) of total revenue
• Operates in over 60 countries with a presence in hospital care, outpatient clinics, and home care

Competitive Position:
B. Braun ranks among the top 10 medical device companies globally. Its pharmaceutical activities are more niche, focusing on high-margin hospital pharmaceutical products rather than broad-based drug manufacturing. The company's diversified portfolio reduces dependency on any single product category.

How Does B. Braun Compare with Major Competitors?

Company	Revenue (2022)	Core Focus	Market Reach	Notable Strengths
B. Braun	€8.1 billion	Hospital supplies, infusion therapy, select APIs	Global, especially Europe and North America	Integrated manufacturing, extensive hospital networks
Fresenius Kabi	€7.3 billion	IV drugs, infusion therapy, biosimilars	Over 100 countries	Broad pharmaceutical portfolio, strong presence in APIs
BD (Becton Dickinson)	€19.9 billion	Medical devices, pharmaceuticals	Worldwide	Innovative drug delivery devices, sterile solutions
Baxter Healthcare	€14.2 billion	IV therapies, renal, and surgical products	Over 100 countries	Diversified healthcare solutions

B. Braun’s revenues and market share trail behind major pharmaceutical-focused firms like Fresenius Kabi and Baxter but compete effectively within hospital-centric segments.

What are B. Braun's Core Strengths?

Integrated Supply Chain

The company owns manufacturing facilities across continents, enabling control over quality and supply. This allows for rapid response to hospital needs and enhances reliability.

Focused Product Portfolio

B. Braun concentrates on infusion systems, surgical instruments, and specific hospital pharmaceuticals. Its expertise lies in high-margin products deployed in critical care, enabling sustained profitability.

Geographic Diversification

Presence in North America, Europe, and Asia provides regional stability and access to emerging markets. The company adapts its product offerings for local regulatory and clinical practices.

R&D Capabilities

Invests approximately €200 million annually in research and development. Key focus areas include needle safety, smart infusion systems, and novel pharmaceuticals for perioperative care.

Strategic Partnerships

Collaborations with biotech firms enable B. Braun to expand its pharmaceutical offerings. Notably, its partnership with BioNTech in vaccine delivery systems exemplifies such strategic moves.

What are the Strategic Opportunities for B. Braun?

Expansion in Biosimilars and Specialty Drugs

Growing demand for biosimilars and personalized therapies offers growth pathways in hospital and outpatient markets. B. Braun can leverage existing distribution channels to introduce generic biologics.

Digital and Smart Infusion Devices

Developing connected infusion systems can reduce medication errors and improve patient safety. B. Braun’s R&D investments support this transition.

Market Penetration in Emerging Economies

Expanding manufacturing and sales in Asia-Pacific and Latin America can capitalize on rising hospital infrastructure development and healthcare spending.

Strategic Acquisitions and Collaborations

Targeted acquisitions of innovative biotech firms can augment B. Braun’s portfolio of specialty pharmaceuticals and APIs.

Complying with Regulatory Changes

Proactive adaptation to evolving regulatory standards in the US (FDA), EU (EMA), and emerging markets ensures uninterrupted product access and competitive advantage.

What are the Challenges Facing B. Braun?

• Limited presence in broad-spectrum pharmaceuticals compared to top pharma firms.
• Regulatory complexity in diverse markets restricts rapid product launches.
• The hospital-centric business model faces pressures from outpatient and home care shifts.
• Competition from large pharma firms entering hospital supply segments with integrated pharmaceutical and device solutions.

Key Takeaways

• B. Braun maintains a prominent position within hospital-focused healthcare segments, demonstrating strengths in integrated manufacturing, geographic reach, and product specialization.
• It operates a niche pharmaceutical segment with growth potential in biosimilars, specialty therapies, and digital health.
• Strategic expansion into emerging markets and collaborations with biotech firms can mitigate growth limitations.
• Competition from diversified pharma companies and shifts toward outpatient care remain significant external pressures.

FAQs

1. What percentage of B. Braun’s revenue comes from pharmaceuticals?
Approximately 12% (€972 million of €8.1 billion total).

2. Which regions are B. Braun’s primary markets?
Europe, North America, and Asia.

3. Is B. Braun involved in biosimilar development?
Not extensively but explores biosimilars and specialty therapies through strategic collaborations.

4. How does B. Braun differentiate its product offerings?
Through integrated manufacturing, focus on hospital infusion and surgical products, and digital health solutions.

5. What growth opportunities exist for B. Braun in the next five years?
Expansion in biosimilars, digital infusion systems, and emerging markets; acquisitions of biotech firms; alignments with regulatory trends.

References

1. B. Braun Group. (2022). Annual Report 2022. Retrieved from https://www.bbraun.com
2. MarketsandMarkets. (2023). Infusion Therapy Devices Market.
3. Statista. (2023). Top Medical Device Companies Worldwide [Data set].
4. Forth, K. (2022). Strategic Review of Hospital Pharmaceutical Industry. Journal of Healthcare Business.